Rescop Opens Offices in UK and Australia
Rescop )Regulatory System Compliance Partners) has opened new offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners) has opened new offices in the UK and Australia. This expansion follows the opening of branches in Belgium and the US last year.
“The move was required to accommodate both our current and future growth in EU and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
The company was found in 2005 by Piet Vervoort and Björn Aalbers. Its headquarters is in Den Bosch, The Netherlands, and it now has eight offices. It supplies GxP compliance software and services, and assists in the following areas: system life cycle management; commissioning, qualification and validation; change management; IT Delivery and Support; and training
Read the release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
